Gemcitabine as single-agent therapy in the management of advanced breast cancer

ONCOLOGY

Volumn 15, Issue 2 SUPPL. 3, 2001, Pages 11-14

  Seidman, Andrew D ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; DRUG DERIVATIVE; GEMCITABINE;

BREAST TUMOR; CHEMISTRY; FEMALE; HUMAN; METASTASIS; PALLIATIVE THERAPY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; REVIEW;

ANTIMETABOLITES, ANTINEOPLASTIC; BREAST NEOPLASMS; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; DEOXYCYTIDINE; FEMALE; HUMANS; NEOPLASM METASTASIS; PALLIATIVE CARE;

EID: 0035260635     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Fornier M, Munster P, Seidman AD: An update on the management of metastatic breast cancer. Oncology 13:1-12, 1999.
2. Hortobagyi GN, Theriault RL, Porter L, et al: Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N Engl J Med 335:1785-1791, 1996.
3. Seidman AD, Gollamudi S: Combining chemotherapy and radiotherapy for metastatic breast cancer: Opportunities and obstacles. Adv Oncol 14:25-29, 1998.
4. Shak S: Overview of the trastuzumab anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Semin Oncol 26(4 suppl 12):71-77, 1999.
5. D'Andrea G, Seidman AD: Docetaxel and paclitaxel for breast cancer: Present status and future prospects. Semin Oncol 24(suppl 13):S13-S17, 1997.
6. Seidman AD, Hudis CA, Albanell J, et al: Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol 16:3353-3361, 1998.
7. Nabholtz JM, Falkson G, Campos D, et al: A phase III trial comparing doxorubicin and docetaxel to doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer (abstract 485). Proc Am Soc Clin Oncol 18:127a, 1999.
8. Seidman AD, Tiersten A, Hudis C, et al: Phase II trial of paclitaxel by 3-hour infusion as initial and as salvage chemotherapy for metastatic breast cancer. J din Oncol 13:2575-2581, 1995.
9. Sparano JA: Taxanes for breast cancer: An evidence-based review of randomized phase II and phase III trials. Clin Breast Cancer 1:32-40, 2000.
10. Sledge GW, Neuberg D, Ingle J, et al: Phase III trial of doxorubicin vs paclitaxel vs doxorubicin + paclitaxel as first-line therapy for metastatic breast cancer: An Intergroup trial (abstract 2). Proc Am Soc Clin Oncol 16:1a, 1997.
11. Munster P, Seidman AD: Management of metastatic breast cancer: Reasons for optimism. Oncology Special Edition 2:101-104, 1999.
12. Nabholtz JM, Senn JH, Bezwoda WR, et al: Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing therapy. J Clin Oncol 17:1413-1424, 1999.
13. Bishop J, Dewar J, Toner GC, et al: Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer. J Clin Oncol 17:2355-2364, 1999.
14. Joensuu H, Holli K, Heikkinen M, et al: Combination chemotherapy versus single-agent therapy as first- and second-line treatment in metastatic breast cancer: A prospective randomized trial. J Clin Oncol 16:3720-3730, 1998.